BevCanna Enterprises

ZYNERBA PHARMACEUTICALS NASDAQZYNE STOCK QUOTE

https://zynerba.com/

LATEST NEWS FROM ZYNERBA PHARMACEUTICALS

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021

Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021

Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights

Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference

Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference

Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual M

Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting

Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Zynerba Pharmaceuticals, Inc. – ZYNE

Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting

Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Notice of Settlement of Derivative Actions

Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference

Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Presents Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting

Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting

Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference